Comparison

AMGEN INC (AMGN) vs GILEAD SCIENCES, INC. (GILD)

The same filed metrics for both companies, side by side.

What each names as a risk in its own annual report, how each is priced against its own history, and the tracked managers whose latest 13F reports a position in both.

Financials

AMGN

AMGEN INC

Drug Manufacturers—General

Revenue, FY25: $36.75B
Net income: $7.71B
Operating cash flow: $9.96B
Free cash flow: $8.1B
Net margin: 20.98%
Operating margin: 24.71%
Gross margin: 67.25%

GILD

GILEAD SCIENCES, INC.

Drug Manufacturers—General

Revenue, FY25: $29.44B
Net income: $8.51B
Operating cash flow: $10.02B
Free cash flow: -
Net margin: 28.90%
Operating margin: 34.04%
Gross margin: 78.83%

Head-to-head

Filed growth, quality and valuation, read against each company’s own history rather than against the other side.

Metric	AMGN	GILD
Revenue growth, latest filed year	+9.95%	+2.40%
Piotroski F-score	7 of 9	8 of 9
P/E against its own history	about normal	-

What each says it is exposed to

From Item 1A of each company’s most recent 10-K.

AMGN

FDA approval
Reimbursement
Cybersecurity
Litigation
China
Tax

And 20 more.

GILD

Reimbursement
FDA approval
Litigation
Cybersecurity
Currency moves
Tariffs

And 20 more.

Tracked managers holding both

Dodge & Cox Dodge & Cox 0.00% · 1.57%
Joel Greenblatt Gotham Asset Management 0.04% · 0.11%

Updated Aug 6, 2026 · the newer of the two companies' filings